Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating
Truist Financial Remains a Buy on Praxis Precision Medicines (PRAX)
Praxis Tech Maximizes PIX Approval Ratios in Brazil With New Cascading Feature
Praxis Precision Medicines Presents on Ulixacaltamide Essential3 Program at the Movement Disorders Society 2024 International Congress
The Top Five Long Crowded Stocks in Each U.S. Sector
TD Cowen Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating
TD Cowen analyst Ritu Baral maintains $Praxis Precision Medicines(PRAX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 46.8% and a total average return of 10.5%